| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |